$EVOK
Evoke Pharma Inc

2016 Q2 Form 10-Q Financial Statement

#000156459016024351 Filed on August 15, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2015 Q4 2015 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $800.0K $840.0K $980.0K
YoY Change -18.37% 13.51% 58.06%
% of Gross Profit
Research & Development $2.095M $1.708M $2.188M
YoY Change -4.25% -21.51% -23.89%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.898M $1.708M $2.188M
YoY Change 32.43% -21.51% -37.34%
Operating Profit
YoY Change
Interest Expense -$70.00K -$70.00K -$80.00K
YoY Change -12.5% 600.0% 33.33%
% of Operating Profit
Other Income/Expense, Net -$72.69K
YoY Change
Pretax Income -$2.970M -$2.620M -$3.240M
YoY Change -8.33% -10.27% -8.73%
Income Tax
% Of Pretax Income
Net Earnings -$2.970M -$2.624M -$3.241M
YoY Change -8.35% -10.13% -8.62%
Net Earnings / Revenue
Basic Earnings Per Share -$0.41
Diluted Earnings Per Share -$411.4K -$367.5K -$521.7K
COMMON SHARES
Basic Shares Outstanding 7.218M
Diluted Shares Outstanding 7.218M

Balance Sheet

Concept 2016 Q2 2015 Q4 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.130M $8.690M $9.880M
YoY Change -58.2% -38.63% -38.44%
Cash & Equivalents $4.130M $8.691M $9.883M
Short-Term Investments
Other Short-Term Assets $510.0K $830.0K $730.0K
YoY Change -30.14% 414.14% -17.98%
Inventory
Prepaid Expenses $833.3K
Receivables
Other Receivables
Total Short-Term Assets $4.640M $9.524M $10.61M
YoY Change -56.27% -37.54% -37.35%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $7.997K $0.00
YoY Change -84.92% -100.0%
Total Long-Term Assets $0.00 $7.997K $0.00
YoY Change -84.92% -100.0%
TOTAL ASSETS
Total Short-Term Assets $4.640M $9.524M $10.61M
Total Long-Term Assets $0.00 $7.997K $0.00
Total Assets $4.640M $9.532M $10.61M
YoY Change -56.27% -37.7% -37.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.260M $930.0K $1.370M
YoY Change -8.03% -7.92% 5.38%
Accrued Expenses $500.0K $760.0K $560.0K
YoY Change -10.71% 8.57% 3.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.400M $146.1K $1.250M
YoY Change 252.0% 15.18%
Total Short-Term Liabilities $6.160M $1.834M $3.190M
YoY Change 93.1% -0.73% 73.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $4.233M $3.100M
YoY Change -100.0% 0.87%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $4.233M $3.100M
YoY Change -100.0% 0.87% 15400.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.160M $1.834M $3.190M
Total Long-Term Liabilities $0.00 $4.233M $3.100M
Total Liabilities $6.163M $6.067M $6.300M
YoY Change -2.17% 0.38% 239.82%
SHAREHOLDERS EQUITY
Retained Earnings -$54.26M -$48.06M
YoY Change 33.73%
Common Stock $52.73M $51.53M
YoY Change 14.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.527M $3.465M $4.310M
YoY Change
Total Liabilities & Shareholders Equity $4.636M $9.532M $10.61M
YoY Change -56.3% -37.42% -37.67%

Cashflow Statement

Concept 2016 Q2 2015 Q4 2015 Q2
OPERATING ACTIVITIES
Net Income -$2.970M -$2.624M -$3.241M
YoY Change -8.35% -10.13% -8.62%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.230M -$2.460M -$2.540M
YoY Change -12.2% -2.38% -17.26%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 260.0K 400.0K 740.0K
YoY Change -64.86% -91.11% -127.21%
NET CHANGE
Cash From Operating Activities -2.230M -2.460M -2.540M
Cash From Investing Activities
Cash From Financing Activities 260.0K 400.0K 740.0K
Net Change In Cash -1.970M -2.060M -1.800M
YoY Change 9.44% -204.04% -68.91%
FREE CASH FLOW
Cash From Operating Activities -$2.230M -$2.460M -$2.540M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-72694
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-152133
CY2016Q2 us-gaap Liabilities
Liabilities
6163285
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
729
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
2897804
CY2015Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2188138
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
802655
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54256519
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
52728877
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.10
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7291841
CY2016Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2095149
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4636372
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7291841
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
-1526913
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
51524821
CY2016Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1447777
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4110225
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4233059
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
146052
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1834440
us-gaap Net Income Loss
NetIncomeLoss
-6195907
us-gaap Net Income Loss
NetIncomeLoss
-6761911
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.86
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7192791
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-3241163
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7217577
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6212803
CY2016Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
99000
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
34067
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6157226
us-gaap Share Based Compensation
ShareBasedCompensation
846042
us-gaap Share Based Compensation
ShareBasedCompensation
756138
us-gaap Paid In Kind Interest
PaidInKindInterest
20724
us-gaap Paid In Kind Interest
PaidInKindInterest
30348
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
6374
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-333952
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-214845
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
75062
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
227700
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4920127
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5539254
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
358023
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1266533
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
358023
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1266533
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4562104
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4272721
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14155809
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9883088
us-gaap Interest Paid
InterestPaid
125813
us-gaap Interest Paid
InterestPaid
104500
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
137812
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&nbsp;&nbsp;Actual results could differ materially from those estimates.&nbsp;&nbsp;</p></div>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2007-01-29
CY2016Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
CY2015Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1208589
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1450537
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1211910
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
evok Legal Accounting And Filing Fees
LegalAccountingAndFilingFees
138000
CY2015Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
111000
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
23288
CY2016Q2 us-gaap Share Based Compensation
ShareBasedCompensation
427130
CY2015Q2 us-gaap Share Based Compensation
ShareBasedCompensation
384538
CY2016Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y1M6D

Files In Submission

Name View Source Status
0001564590-16-024351-index-headers.html Edgar Link pending
0001564590-16-024351-index.html Edgar Link pending
0001564590-16-024351.txt Edgar Link pending
0001564590-16-024351-xbrl.zip Edgar Link pending
evok-10q_20160630.htm Edgar Link pending
evok-20160630.xml Edgar Link completed
evok-20160630.xsd Edgar Link pending
evok-20160630_cal.xml Edgar Link unprocessable
evok-20160630_def.xml Edgar Link unprocessable
evok-20160630_lab.xml Edgar Link unprocessable
evok-20160630_pre.xml Edgar Link unprocessable
evok-ex103_350.htm Edgar Link pending
evok-ex311_11.htm Edgar Link pending
evok-ex312_10.htm Edgar Link pending
evok-ex321_9.htm Edgar Link pending
evok-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending